title: Association of Immunotherapies With Outcomes in Relapsing-Remitting Multiple Sclerosis.
abstract: OBJECTIVE
  What immunotherapies for multiple sclerosis are associated with the greatest benefit and highest risk of discontinuation due to adverse events in patients with relapsing-remitting multiple sclerosis?
  
  
  CONCLUSIONS
  Alemtuzumab, natalizumab, and fingolimod were associated with the greatest benefit with regard to relapse prevention. Their association with prevention of disability worsening was unclear. Fingolimod was associated with a high risk of treatment discontinuation due to adverse events.
authors.affiliation: Neuroepidemiology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
authors.forename: Irene
authors.initials: I
authors.lastname: Tramacere
authors.affiliation: Italian Cochrane Centre, Department of Diagnostic, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Modena, Italy.
authors.forename: Cinzia
authors.initials: C
authors.lastname: Del Giovane
authors.affiliation: Scientific Direction, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
authors.forename: Graziella
authors.initials: G
authors.lastname: Filippini
mesh_terms: D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007167:Immunotherapy; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents